# Cequent Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cequent-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.cequentpharma.com
- Total disclosed funding: $18M
- Latest round: Series B (Oct 30, 2009)
- Investors on record: 6

## About

Cequent Pharmaceuticals is based in US and operates as a biopharmaceutical company which develops RNAi-based therapies.

## Funding rounds

- Series B, Oct 30, 2009, $2.6M — Ampersand, New England Partners, Novartis Venture Fund, Pappas Capital
- Series A, Aug 15, 2008, $1.4M — Ampersand, New England Partners, Nexus Group, Novartis Venture Fund, Pappas Capital, Yasuda Enterprise Development
- Series A, Jan 22, 2008, $4.5M — Ampersand, New England Partners, Nexus Group, Novartis Venture Fund, Pappas Capital
- Series A, Jun 18, 2007, $3M — Ampersand, Nexus Group, Novartis Venture Fund, Pappas Capital
- Series A, Nov 1, 2006, $6M — Ampersand, New England Partners, Nexus Group, Pappas Capital

## Investors

- Ampersand (https://capitalatlas.ai/funds/ampersand) — Series A, Series B
- New England Partners (https://capitalatlas.ai/funds/new-england-partners) — Series A, Series B
- Nexus Group (https://capitalatlas.ai/funds/nexus-group) — Series A
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series A